Drug Patent Expirations in January 2013

Drug Patent Expirations for January 2013

Tradename Applicant Generic Name Patent Number Patent Expiration
LUPRON DEPOT-PED Abbott Endocrine leuprolide acetate 5,480,656 Jan 2, 2013
LUPRON DEPOT Abbott Endocrine leuprolide acetate 5,643,607 Jan 2, 2013
LUPRON DEPOT-PED Abbott Endocrine leuprolide acetate 5,643,607 Jan 2, 2013
LUPRON DEPOT Abbott Endocrine leuprolide acetate 5,480,656 Jan 2, 2013
TAXOTERE Sanofi Aventis Us docetaxel 5,750,561*PED Jan 3, 2013
TAXOTERE Sanofi Aventis Us docetaxel 5,698,582*PED Jan 3, 2013
TAXOTERE Sanofi Aventis Us docetaxel 5,714,512*PED Jan 3, 2013
ACCOLATE Astrazeneca zafirlukast 5,482,963 Jan 9, 2013
LOTRONEX Prometheus Labs alosetron hydrochloride 5,360,800 Jan 13, 2013
IRESSA Astrazeneca gefitinib 5,616,582 Jan 19, 2013
IRESSA Astrazeneca gefitinib 5,457,105 Jan 19, 2013
MERIDIA Abbott sibutramine hydrochloride 5,436,272*PED Jan 25, 2013
STARLIX Novartis nateglinide 5,488,150 Jan 30, 2013
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.

Comments are closed.